Document is current
Any future updates will be listed below
-
Authors
Quintanilha, Julia C. F. http://orcid.org/0000-0001-6908-4474
Kelly, William Kevin
Innocenti, Federico http://orcid.org/0000-0001-9247-979X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U10CA180821, U10CA180882, UG1CA233373)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
- License Information
-
More Information
Article History
Received: 9 October 2023
Revised: 10 June 2024
Accepted: 17 June 2024
First Online: 12 July 2024
Competing interests
: JCFQ is an employee of Foundation Medicine, a wholly owned subsidiary of Roche, and receives stocks from Roche. FI is an employee of AbbVie and receives stocks from the company. JCFQ and FI are coinventors of a United States Patent: “Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, FI, JCFQ., Lin D., Owzar K., Wang J. Serial number 11,028,448. WKK, DO- no conflicts of interest.
